Study guide

11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection

Key Takeaways Explain This Topic AI

Calcineurin inhibitors cause hyperkalemia, hypomagnesemia, hypertension and hyperglycemia; tacrolimus is the more diabetogenic and cyclosporine the more hyperlipidemic of the two.

mTOR inhibitors (sirolimus, everolimus) commonly cause hyperlipidemia, impaired wound healing and proteinuria.

KDOQI 2020 recommends limiting sodium to under 2.3 g/day after transplant (1C) and suggests a Mediterranean diet to improve lipid profiles (2C).

KDOQI 2020 suggests not routinely prescribing long-chain omega-3 fatty acids to reduce rejection or improve graft survival (2D).

Commonly used long-term targets for a stable graft are about 0.8–1.0 g protein/kg and energy matched to a healthy weight, with protein lowered as graft function declines.

Last updated: September 2026

The shift from dialysis restrictions to chronic-disease prevention

Once a graft is stable, often within 2–3 months, most dialysis-era restrictions can be lifted. Serum potassium and phosphorus are managed to their actual values rather than restricted by habit, and fluid is usually generous. The leading long-term threats to a recipient are cardiovascular disease, post-transplant diabetes, obesity, bone disease, infection, cancer and chronic graft injury . Nutrition care therefore shifts from restriction to prevention.

KDOQI 2020 extends several statements to transplant recipients (written as "posttransplantation"):

Energy: 25–35 kcal/kg/day for metabolically stable adults (3.1.1, OPINION for transplant).

Sodium: less than 100 mmol/day (<2.3 g/day) to reduce blood pressure and improve volume control (6.5.1, grade 1C).

Potassium: adjust intake to keep serum potassium normal (6.4.1).

Mediterranean diet: may improve lipid profiles (3.3.1, grade 2C).

Omega-3 fatty acids: do not prescribe routinely to reduce rejection or improve graft survival (4.3.7, grade 2D).

Vitamin D: correct 25(OH)D deficiency with cholecalciferol or ergocalciferol (5.3.1).

Monitoring: check body weight and BMI at least every 3 months after transplant (1.1.5). Both underweight and overweight or obesity predict higher mortality in recipients (1.1.10).

Long-term protein targets in commonly used references are about 0.8–1.0 g/kg/day for a well-functioning graft. Some references suggest the lower end without diabetes. If the graft fails and GFR falls, protein advice follows the CKD stage.

Immunosuppressants and their nutrition effects

Drug class (examples) Main nutrition-related effects Dietitian response

Calcineurin inhibitors: tacrolimus, cyclosporine Hyperkalemia, hypomagnesemia, hypertension, hyperglycemia (tacrolimus more so), hyperlipidemia (cyclosporine more so), tremor; cyclosporine causes gingival overgrowth Monitor potassium, magnesium, glucose and lipids; avoid grapefruit, pomelo and Seville orange; take at consistent times relative to meals

Antimetabolites: mycophenolate, azathioprine Nausea, diarrhea and abdominal pain (mycophenolate); marrow suppression Small frequent meals; replace fluid and electrolyte losses; report persistent diarrhea

mTOR inhibitors: sirolimus, everolimus Hyperlipidemia (especially triglycerides), impaired wound healing, mouth ulcers, proteinuria, edema Lipid-lowering diet; protein and wound nutrition around surgery

Corticosteroids: prednisone Hyperglycemia, increased appetite, weight gain, sodium retention, muscle wasting, bone loss Carbohydrate and portion counseling; calcium and vitamin D adequacy; resistance exercise

Costimulation blocker: belatacept Fewer metabolic effects than calcineurin inhibitors Standard healthy-diet counseling

Infection prophylaxis: trimethoprim-sulfamethoxazole Raises serum potassium and creatinine Consider before restricting dietary potassium

Post-transplant diabetes mellitus (PTDM)

PTDM develops in a meaningful share of recipients within the first year. Risk factors include older age, obesity, family history, hepatitis C, tacrolimus and corticosteroids. Key points:

Diagnose PTDM once the patient is stable on maintenance immunosuppression , not in the first weeks of stress hyperglycemia.

An oral glucose tolerance test detects more cases than fasting glucose. HbA1c used alone can miss PTDM early after transplant, because anemia, blood loss and transfusion distort it.

Treatment starts with lifestyle change (weight management, carbohydrate quality, physical activity) and adds medications chosen by the team.

Weight gain and obesity

Appetite improves once uremia resolves and corticosteroids stimulate eating, so weight gain in the first year is common. Rising BMI raises the risk of PTDM, hypertension, dyslipidemia and cardiovascular events. Start preventive counseling before the weight arrives: set a goal weight, plan portions, limit sugary drinks and schedule regular weigh-ins.

Cardiovascular risk: blood pressure and lipids

Blood pressure: sodium under 2.3 g/day (KDOQI) combined with a DASH or Mediterranean pattern, weight control and limited alcohol.

Lipids: calcineurin and mTOR inhibitors and steroids worsen lipids. KDIGO's 2013 lipid guideline suggests statin treatment for adult kidney transplant recipients . Some statins interact with cyclosporine, so the team chooses the agent and dose. The dietitian supports a pattern low in saturated and trans fat, with more fiber, fish and plant proteins.

Bone and mineral disease after transplant

Pre-existing renal osteodystrophy, steroids and persistent hyperparathyroidism cause early bone loss.

Tertiary hyperparathyroidism can cause hypercalcemia with low phosphorus after transplant.

Ensure adequate calcium intake from food and correct vitamin D deficiency.

Encourage weight-bearing and resistance exercise.

Medication decisions (calcitriol, antiresorptives, calcimimetics or parathyroidectomy) belong to the team. They follow KDIGO's CKD-MBD guidance on bone-density testing and treatment in transplant recipients.

Anemia, magnesium and potassium in the long term

Post-transplant anemia is common and often reflects iron deficiency, drug effects or declining graft function. KDIGO's 2026 anemia guideline includes kidney transplant recipients among people not on dialysis when choosing the hemoglobin at which to start an ESA. Persistent hypomagnesemia from calcineurin inhibitors often needs ongoing magnesium supplements and magnesium-rich foods (nuts, legumes, whole grains) as potassium allows. Unexplained hyperkalemia should trigger a review of calcineurin-inhibitor levels, trimethoprim-sulfamethoxazole, RAAS blockers and metabolic acidosis before a strict potassium diet is imposed.

When the graft declines

Transplant recipients are staged by eGFR and albuminuria like anyone with CKD. As function falls, nutrition care returns to CKD principles: attention to sodium, potassium, phosphorus and acid–base balance, and protein adjusted to stage and metabolic stability. If dialysis is needed again, dialysis protein targets (1.0–1.2 g/kg) apply. The patient may also be evaluated for a second transplant, so nutrition status matters again.

Long-term follow-up checklist for the dietitian

Weight, BMI and waist trend at least every 3 months (KDOQI 1.1.5).

Glucose and HbA1c, lipids, blood pressure, potassium, magnesium, phosphorus, calcium and 25(OH)D.

Diet quality: sodium, saturated fat, sugar-sweetened beverages, fiber and alcohol.

Food safety, grapefruit-family avoidance and supplement review at every visit.

Physical activity and bone health.